<p>Cerus Corporation (NASDAQ:CERS - 获取免费报告) 在八月份的空头头寸大幅增加。截至 8 月 15 日，空头头寸总计为 9,740,000 股，比 7 月 31 日的 7,010,000 股增加了 38.9%。根据平均每日交易量 1,240,000 股，目前的覆盖天数比率为 7.9 天。</p>
<h2>Cerus 的机构交易</h2>
<p>几家大型投资者最近买卖了该公司的股票。Wasatch Advisors LP 在第二季度将其在 Cerus 的持股增加了 2.6%。Wasatch Advisors LP 目前拥有 8,533,758 股生物技术公司的股票，价值 12,033,000 美元，在上个季度又购买了 213,917 股。Millennium Management LLC 在第一季度将其在 Cerus 的持股增加了 12.0%。Millennium Management LLC 目前拥有 3,222,327 股生物技术公司的股票，价值 4,479,000 美元，在此期间又购买了 344,395 股。Acadian Asset Management LLC 在第二季度将其在 Cerus 的持股增加了 38.6%。Acadian Asset Management LLC 目前拥有 2,632,304 股生物技术公司的股票，价值 3,710,000 美元，在此期间又购买了 733,683 股。Ieq Capital LLC 在第二季度将其在 Cerus 的持股增加了 4.2%。Ieq Capital LLC 目前拥有 2,418,263 股生物技术公司的股票，价值 3,410,000 美元，在此期间又购买了 97,467 股。最后，Charles Schwab Investment Management Inc.在第一季度将其在 Cerus 的持股增加了 6.5%。Charles Schwab Investment Management Inc.目前拥有 1,774,137 股生物技术公司的股票，价值 2,466,000 美元，在此期间又购买了 107,771 股。机构投资者和对冲基金持有该公司 78.37% 的股票。</p>
<h2>Cerus 股票表现</h2>
<p>CERS 的股票在周一开盘价为 1.33 美元。该公司的市值为 2.5496 亿美元，市盈率为-13.30，贝塔值为 1.63。该公司的债务与股本比率为 1.01，流动比率为 2.00，速动比率为 1.35。该公司的 50 日简单移动平均线为 1.34 美元，200 日简单移动平均线为 1.37 美元。Cerus 的 1 年最低价为 1.12 美元，1 年最高价为 2.24 美元。</p>
<p>Cerus (NASDAQ:CERS - 获取免费报告) 最近于 8 月 5 日发布了其财报。这家生物技术公司报告的每股收益（EPS）为-0.03 美元，低于分析师一致预期的-0.02 美元，差距为-0.01 美元。该公司在该季度的收入为 6010 万美元，而分析师预期为 5180 万美元。Cerus 的净利润率为-9.81%，股本回报率为-33.77%。Cerus 已将其 2025 财年的指引设定为每股收益。股票分析师预测 Cerus 在当前财年将发布-0.08 的每股收益。</p>
<h2>关于 Cerus</h2>
<p>(获取免费报告)</p>
<p>Cerus Corporation 是一家生物医学产品公司。该公司专注于开发和商业化 INTERCEPT 血液系统，以增强血液安全性。其 INTERCEPT 血液系统是一种控制生物复制的专有技术，旨在减少用于输血的捐赠血液成分中的血源性病原体。</p>
<h2>另请参阅</h2>
<ul>
<li>我们更看好的五只股票，而不是 Cerus</li>
<li>复利及其在投资中的重要性</li>
<li>2 只可能在美联储降息时暴涨的股票</li>
<li>想在下跌趋势中获利？下跌趋势解析。</li>
<li>2025 年市场表现优于大盘的 3 只金融科技股票</li>
<li>内部交易可能不会告诉你你想的那样</li>
<li>潜在的降息可能使这些公司受益</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在 Cerus 吗？</h2>
<p>在你考虑 Cerus 之前，你会想听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐，现在就买入，以便在更广泛的市场注意到之前……而 Cerus 并不在名单上。</p>
<p>虽然 Cerus 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

CERS

<p>Cerus Corporation（纳斯达克代码：CERS）在八月份的空头头寸显著增加了 38.9%，截至 8 月 15 日，总计达到 9,740,000 股。根据每日平均交易量 1,240,000 股，覆盖天数比率为 7.9 天。机构投资者持有该公司 78.37% 的股份，其中 Wasatch Advisors 和 Millennium Management 等公司的持股显著增加。Cerus 报告的季度每股收益为（$0.03），未达到预期，但收入超出预期，达到 6010 万美元。该股开盘价为$1.33，市值为 2.5496 亿美元</p>

<p>Cerus Corporation (NASDAQ:CERS - Get Free Report) was the target of a large increase in short interest in the month of August. As of August 15th, there was short interest totaling 9,740,000 shares, anincreaseof38.9% from the July 31st total of 7,010,000 shares. Based on an average daily volume of 1,240,000 shares, the days-to-cover ratio is currently 7.9 days. Based on an average daily volume of 1,240,000 shares, the days-to-cover ratio is currently 7.9 days.</p>
<div class="lb-trans"><p>Cerus Corporation (NASDAQ:CERS - 获取免费报告) 在八月份的空头头寸大幅增加。截至 8 月 15 日，空头头寸总计为 9,740,000 股，比 7 月 31 日的 7,010,000 股增加了 38.9%。根据平均每日交易量 1,240,000 股，目前的覆盖天数比率为 7.9 天。</p>
</div><h2>Institutional Trading of Cerus</h2>
<div class="lb-trans"><h2>Cerus 的机构交易</h2>
</div><p>Several large investors have recently bought and sold shares of the company. Wasatch Advisors LP grew its position in shares of Cerus by 2.6% during the second quarter. Wasatch Advisors LP now owns 8,533,758 shares of the biotechnology company's stock worth $12,033,000 after buying an additional 213,917 shares in the last quarter. Millennium Management LLC boosted its holdings in shares of Cerus by 12.0% in the 1st quarter. Millennium Management LLC now owns 3,222,327 shares of the biotechnology company's stock valued at $4,479,000 after buying an additional 344,395 shares during the period. Acadian Asset Management LLC boosted its holdings in shares of Cerus by 38.6% in the 2nd quarter. Acadian Asset Management LLC now owns 2,632,304 shares of the biotechnology company's stock valued at $3,710,000 after buying an additional 733,683 shares during the period. Ieq Capital LLC boosted its holdings in shares of Cerus by 4.2% during the second quarter. Ieq Capital LLC now owns 2,418,263 shares of the biotechnology company's stock valued at $3,410,000 after acquiring an additional 97,467 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its holdings in shares of Cerus by 6.5% during the first quarter. Charles Schwab Investment Management Inc. now owns 1,774,137 shares of the biotechnology company's stock valued at $2,466,000 after acquiring an additional 107,771 shares during the period. Institutional investors and hedge funds own 78.37% of the company's stock.</p>
<div class="lb-trans"><p>几家大型投资者最近买卖了该公司的股票。Wasatch Advisors LP 在第二季度将其在 Cerus 的持股增加了 2.6%。Wasatch Advisors LP 目前拥有 8,533,758 股生物技术公司的股票，价值 12,033,000 美元，在上个季度又购买了 213,917 股。Millennium Management LLC 在第一季度将其在 Cerus 的持股增加了 12.0%。Millennium Management LLC 目前拥有 3,222,327 股生物技术公司的股票，价值 4,479,000 美元，在此期间又购买了 344,395 股。Acadian Asset Management LLC 在第二季度将其在 Cerus 的持股增加了 38.6%。Acadian Asset Management LLC 目前拥有 2,632,304 股生物技术公司的股票，价值 3,710,000 美元，在此期间又购买了 733,683 股。Ieq Capital LLC 在第二季度将其在 Cerus 的持股增加了 4.2%。Ieq Capital LLC 目前拥有 2,418,263 股生物技术公司的股票，价值 3,410,000 美元，在此期间又购买了 97,467 股。最后，Charles Schwab Investment Management Inc.在第一季度将其在 Cerus 的持股增加了 6.5%。Charles Schwab Investment Management Inc.目前拥有 1,774,137 股生物技术公司的股票，价值 2,466,000 美元，在此期间又购买了 107,771 股。机构投资者和对冲基金持有该公司 78.37% 的股票。</p>
</div><h2>Cerus Stock Performance</h2>
<div class="lb-trans"><h2>Cerus 股票表现</h2>
</div><p>Shares of CERS opened at $1.33 on Monday. The stock has a market cap of $254.96 million, a price-to-earnings ratio of -13.30 and a beta of 1.63. The company has a debt-to-equity ratio of 1.01, a current ratio of 2.00 and a quick ratio of 1.35. The firm has a 50 day simple moving average of $1.34 and a 200-day simple moving average of $1.37. Cerus has a 1-year low of $1.12 and a 1-year high of $2.24.</p>
<div class="lb-trans"><p>CERS 的股票在周一开盘价为 1.33 美元。该公司的市值为 2.5496 亿美元，市盈率为-13.30，贝塔值为 1.63。该公司的债务与股本比率为 1.01，流动比率为 2.00，速动比率为 1.35。该公司的 50 日简单移动平均线为 1.34 美元，200 日简单移动平均线为 1.37 美元。Cerus 的 1 年最低价为 1.12 美元，1 年最高价为 2.24 美元。</p>
</div><p>Cerus (NASDAQ:CERS - Get Free Report) last released its earnings results on Tuesday, August 5th. The biotechnology company reported ($0.03) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.02) by ($0.01). The firm had revenue of $60.10 million during the quarter, compared to analysts' expectations of $51.80 million. Cerus had a negative net margin of 9.81% and a negative return on equity of 33.77%. Cerus has set its FY 2025 guidance at EPS. Equities analysts forecast that Cerus will post -0.08 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Cerus (NASDAQ:CERS - 获取免费报告) 最近于 8 月 5 日发布了其财报。这家生物技术公司报告的每股收益（EPS）为-0.03 美元，低于分析师一致预期的-0.02 美元，差距为-0.01 美元。该公司在该季度的收入为 6010 万美元，而分析师预期为 5180 万美元。Cerus 的净利润率为-9.81%，股本回报率为-33.77%。Cerus 已将其 2025 财年的指引设定为每股收益。股票分析师预测 Cerus 在当前财年将发布-0.08 的每股收益。</p>
</div><h2>About Cerus</h2>
<div class="lb-trans"><h2>关于 Cerus</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.</p>
<div class="lb-trans"><p>Cerus Corporation 是一家生物医学产品公司。该公司专注于开发和商业化 INTERCEPT 血液系统，以增强血液安全性。其 INTERCEPT 血液系统是一种控制生物复制的专有技术，旨在减少用于输血的捐赠血液成分中的血源性病原体。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另请参阅</h2>
</div><ul>
<li>Five stocks we like better than Cerus</li>
<li>Compound Interest and Why It Matters When Investing</li>
<li>2 Stocks That Could Rocket on a Fed Rate Cut</li>
<li>Want to Profit on the Downtrend? Downtrends, Explained.</li>
<li>3 Fintech Stocks Beating the Market in 2025</li>
<li>Insider Trades May Not Tell You What You Think</li>
<li>Potential Rate Cuts Could Benefit These Firms</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是 Cerus</li>
<li>复利及其在投资中的重要性</li>
<li>2 只可能在美联储降息时暴涨的股票</li>
<li>想在下跌趋势中获利？下跌趋势解析。</li>
<li>2025 年市场表现优于大盘的 3 只金融科技股票</li>
<li>内部交易可能不会告诉你你想的那样</li>
<li>潜在的降息可能使这些公司受益</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Cerus Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 Cerus 吗？</h2>
</div><p>Before you consider Cerus, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Cerus 之前，你会想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cerus wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐，现在就买入，以便在更广泛的市场注意到之前……而 Cerus 并不在名单上。</p>
</div><p>While Cerus currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Cerus 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Cerus 公司（NASDAQ:CERS）在八月份的空头头寸增长了 38.9%